ReviewCancer science2006
Therapeutic potential of RNA interference against cancer.
Review in Cancer science, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 237 citations in OpenAlex.
- Whole-Genome Landscape of Retinal Hemangioblastomas.Translational vision science & technology · 2026Article
- Advances and prospects of RNA delivery nanoplatforms for cancer therapy.Acta pharmaceutica Sinica. B · 2025Review
- siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases.Pharmaceutics · 2022Review
- Coordination-based self-assembled capsules (SACs) for protein, CRISPR-Cas9, DNA and RNA delivery.Chemical science · 2021Review
- The Current Status of Gene Therapy for the Treatment of Cancer.Biologics : targets & therapy · 2021Review
- Polymerized Selenium Nanoparticles for Folate-Receptor-Targeted Delivery of Anti-Luc-siRNA: Potential for Gene Silencing.Biomedicines · 2020Article
- Periodicity and dosage optimization of an RNAi model in eukaryotes cells.BMC bioinformatics · 2019Article
- miR-582-3p and miR-582-5p Suppress Prostate Cancer Metastasis to Bone by Repressing TGF-β Signaling.Molecular therapy. Nucleic acids · 2019Article
- Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides.Oncology letters · 2017Article
- Insights for hepatitis C virus related hepatocellular carcinoma genetic biomarkers: Early diagnosis and therapeutic intervention.World journal of hepatology · 2016Review
- Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma.Journal of Cancer · 2016Article
- Lentivirus-Mediated Short-Hairpin RNA Targeting Protein Phosphatase 4 Regulatory Subunit 1 Inhibits Growth in Breast Cancer.Journal of breast cancer · 2015Article
- Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer.Oncotarget · 2015Article
- RNA interference targeting enhancer of polycomb1 exerts anti-tumor effects in lung cancer.International journal of clinical and experimental pathology · 2015Article
- Lipid nanoparticle delivery systems for siRNA-based therapeutics.Drug delivery and translational research · 2014Article
- A novel platform to enable inhaled naked RNAi medicine for lung cancer.Scientific reports · 2013Article
- Characterization of polyethylene glycol-grafted polyethylenimine and superparamagnetic iron oxide nanoparticles (PEG-g-PEI-SPION) as an MRI-visible vector for siRNA delivery in gastric cancer in vitro and in vivo.Journal of gastroenterology · 2013Article
- Gene therapy for cardiovascular disease mediated by ultrasound and microbubbles.Cardiovascular ultrasound · 2013Review
- Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma.British journal of cancer · 2013Article
- Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the most dramatic events of the past 5 years in the field of molecular biology has been the discovery of RNA interference (RNAi). Although RNAi is an evolutionarily conserved phenomenon for sequence-specific gene silencing in mammalian cells, exogenous small interfering RNA (siRNA) and vector-based short hairpin RNA (shRNA) can also invoke RNAi responses. Both are now not only experimental tools for analyzing gene function but are expected to be excellent avenues for drug target discovery and the emerging class of gene medicine for targeting incurable diseases such as cancer. The success of cancer therapeutic use of RNAi relies on the development of safe and efficacious delivery systems that introduce siRNA and shRNA expression vectors into target tumor cells. For their delivery, a variety of strategies have been used, most of them based on traditional gene therapy delivery systems. In this review, we present siRNA delivery method strategies and discuss the potential of RNAi-based gene therapy in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.